2021 Archives - Aria Pharmaceuticals

A Transformational Year for Aria

2021 was a year of growth and transformational change at Aria Pharmaceuticals. In recognition of our continued evolution, we announced a rebrand to a new name that reflects the artistry and complexity that defines how our company and scientific teams approach medicine, from discovery to clinical research to FDA approval, while always keeping the science our number one priority.

Innovation in Drug Research and Development for Prevalent Chronic Diseases: Proceedings of a Workshop (2021)

Half of all Americans live with at least one chronic disease, such as heart disease, cancer, stroke, or diabetes. Chronic diseases—which are, broadly defined, health conditions that persist for 1 year or longer, that typically require ongoing medical attention, and that can interfere with the activities of daily living (CDC, 2021b)—are a major health concern in the United States and around the world. Chronic diseases are the leading cause of death and disability in the United States and are a leading driver of health care costs (CDC, 2021a).

A New Era of Hope for Idiopathic Pulmonary Fibrosis

Idiopathic pulmonary fibrosis (IPF) is devastating. It causes lung tissue scarring that becomes thicker over time, causing chronic pain and difficulty breathing. However, it’s not just the physical toll of the disease that impacts patients, it’s also a significant decline in quality of life.

Why Aria Pharmaceuticals is upbeat about two novel IPF treatment candidates

Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) recently revealed that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated promising results in preclinical research.

Aria Reports Positive Preclinical Data for 2 New IPF Treatments

TXR-1002 and TXR-1007, two new therapeutic candidates for idiopathic pulmonary fibrosis (IPF) from Aria Pharmaceuticals, demonstrated significant efficacy at reducing tissue scarring and good tolerability in a mouse model of the disease

Aria Pharmaceuticals announces positive in vivo data for two idiopathic pulmonary fibrosis candidates

Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) has announced that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated efficacy and tolerability in preclinical research.

Aria Pharmaceuticals Presents Positive In Vivo Data Showing Two Novel Treatment Candidates Demonstrated Positive Efficacy and Tolerability in Idiopathic Pulmonary Fibrosis Compared to Standard of Care

TXR-1002 and TXR-1007, demonstrated significant efficacy and excellent tolerability in preclinical studies.

Seeking Intelligence Beyond the buzz, is AI just another research tool?

Andrew Radin is interviewed for a Special Report in the July/August Issue of Drug Discovery News

5th Annual IPF Summit: August 25-27, 2021

Aria Pharmaceuticals SVP Anjali Pandey presents the latest IPF data at the 5th Annual IPF Summit

Moneyball Medicine: The Legacy of Stanford’s Biomedical Informatics Program

Harry traveled to the San Francisco Bay Area this summer, and while there he interviewed the co-founders of three local data-driven diagnostics and drug discovery startups, all of whom participated in the same graduate program: the Biomedical Informatics Program at Stanford’s School of Medicine.

News and Events Tag: 2021